B. Kaiser

发表

Pharmacology of Synthetic Thrombin Inhibitors of the Tripeptide Type

J. Hauptmann, B. Kaiser, 1992 .

Pharmacological characterization of a new highly effective synthetic thrombin inhibitor.

F. Markwardt, J. Hauptmann, B. Kaiser, 1985, Biomedica biochimica acta.

Antithrombotic and haemorrhagic effects of synthetic and naturally occurring thrombin inhibitors.

F. Markwardt, B. Kaiser, 1986, Thrombosis research.

Tissue factor pathway inhibitor for cardiovascular disorders

D. Hoppensteadt, J. Fareed, B. Kaiser, 2000 .

Synthetic and recombinant antithrombin drugs.

J. Fareed, J. Walenga, B. Kaiser, 1998, Expert opinion on investigational drugs.

Phospholipase A2 is involved in chemotaxis of human leukocytes.

W. Scheuer, W. Friebe, B. Kaiser, 1999, Advances in experimental medicine and biology.

Oral antithrombin drugs

B. Kaiser, 2007 .

Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis

T. Cohnert, B. Samuelsson, O. Rådmark, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Role of Newer Anti‐Xa and Anti‐IIa Agents for Interventions

B. Kaiser, 2014 .

Comparative studies on the inhibitory spectrum of recombinant hirudin, DuP 714 and heparin on thrombin and factor Xa generation in biochemically defined systems.

J. Fareed, D. Hoppensteadt, B. Kaiser, 1994, Thrombosis research.

Influence of recombinant hirudin and unfractionated heparin on thrombin and factor Xa generation in extrinsic and intrinsic activated systems.

F. Markwardt, J. Fareed, D. Hoppensteadt, 1992, Thrombosis research.

Inactivation of factor Xa by the synthetic inhibitor DX-9065a causes strong anticoagulant and antiplatelet actions in human blood.

J. Fareed, W. Jeske, J. Walenga, 1999, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Tissue factor pathway inhibitor in thrombosis and beyond.

S. Mousa, J. Fareed, O. Iqbal, 2004, Methods in molecular medicine.

DX-9065a, a direct inhibitor of factor Xa.

B. Kaiser, 2006, Cardiovascular drug reviews.

Systemic vascular effects of thrombin and thrombin receptor activating peptide in rats.

B. Kaiser, T. Sicker, E. Glusa, 2001, Thrombosis research.

Visions & Reflections Factor Xa - a promising target for drug development

B. Kaiser, 2002, Cellular and Molecular Life Sciences CMLS.

A survey of venous thrombosis models.

J. Fareed, O. Iqbal, W. Jeske, 2004, Methods in molecular medicine.

Reduction of a benzamidoxime derivative to the corresponding benzamidine in vivo and in vitro.

J. Hauptmann, B. Kaiser, M. Paintz, 1988, Die Pharmazie.

The Lamina Adventitia Is the Major Site of Immune Cell Accumulation in Standard Chow-Fed Apolipoprotein E–Deficient Mice

R. Vollandt, C. Funk, A. Habenicht, 2005, Arteriosclerosis, thrombosis, and vascular biology.

A synthetic inhibitor of factor Xa, DX-9065a, reduces proliferation of vascular smooth muscle cells in vivo in rats.

B. Kaiser, S. Kunitada, J. Fareed, 2000, Thrombosis research.

Antithrombotic Effects of Recombinant Hirudin in Experimental Angioplasty and Intravascular Thrombolysis

F. Markwardt, B. Kaiser, A. Simon, 1990, Thrombosis and Haemostasis.

Status der Thrombophilie-Diagnostik unter besonderer Berücksichtigung molekulargenetischer Aspekte / Diagnosing thrombophilia with particular reference to genetic factors

P. Cullen, M. Neumaier, B. Kaiser, 2009 .

Diagnosing thrombophilia today with particular reference to genetic factors and the antiphospholipid antibody syndrome 1

P. Cullen, M. Neumaier, B. Kaiser, 2009 .

In vitro studies on the effect of activated protein C on platelet activation and thrombin generation.

J. Fareed, D. Hoppensteadt, W. Jeske, 1997, Thrombosis research.

Suppression of cytokine synthesis, integrin expression and chronic inflammation by inhibitors of cytosolic phospholipase A2.

W. Scheuer, W. Friebe, B. Kaiser, 1997, European journal of pharmacology.

Factor Xa Inhibitors as Novel Antithrombotic Agents: Facts and Perspectives

J. Hauptmann, B. Kaiser, 1994 .

State-of-the-Art Review: Factor Xa Versus Factor IIa Inhibitors

B. Kaiser, 1997 .

Anticoagulant and antithrombotic action of the factor Xa inhibitor antistasin (ATS).

J. Hauptmann, B. Kaiser, 1993, Thrombosis research.

Pharmacological survey of recombinant hirudin.

F. Markwardt, G. Fink, B. Kaiser, 1988, Die Pharmazie.

Recombinant TFPI and variants: potential implications in the treatment of cardiovascular disorders.

D. Hoppensteadt, B. Kaiser, J. Fareed, 1998, Expert opinion on investigational drugs.

Anticoagulant and Antithrombotic Actions of Recombinant Hirudin

B. Kaiser, 1991, Seminars in thrombosis and hemostasis.

Tissue factor pathway inhibitor: an update of potential implications in the treatment of cardiovascular disorders

D. Hoppensteadt, J. Fareed, B. Kaiser, 2001, Expert opinion on investigational drugs.

Experimental Studies on the Antithrombotic Action of a Highly Effective Synthetic Thrombin Inhibitor

F. Markwardt, B. Kaiser, 1986, Thrombosis and Haemostasis.

THROMBIN AND FACTOR XA INHIBITORS

B. Kaiser, B. Kaiser, 1998 .

Flow cytometric evaluation of the effect of various thrombin inhibitors on platelet activation in whole blood.

J. Fareed, J. Walenga, B. Kaiser, 1996, Thrombosis Research.

Cutting the cost of South African antiretroviral therapy using newer, safer drugs.

M. Moorhouse, M. Boffito, W. Venter, 2016, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

Recombinant Full-length Tissue Factor Pathway Inhibitor (TFPI) Prevents Thrombus Formation and Rethrombosis after Lysis in a Rabbit Model of Jugular Vein Thrombosis

J. Fareed, B. Kaiser, J. Fareed, 1996, Thrombosis and Haemostasis.

Comparison of the Anticoagulant and Antithrombotic Effects of Synthetic Thrombin and Factor Xa Inhibitors

F. Markwardt, J. Hauptmann, B. Kaiser, 1990, Thrombosis and Haemostasis.

Anticoagulant and Antithrombotic Action of Novel Specific Inhibitors of Thrombin

F. Markwardt, J. Hauptmann, B. Kaiser, 1980, Thrombosis and Haemostasis.

In vitro studies on thrombin generation in citrated, r-hirudinized and heparinized whole blood.

F. Markwardt, D. Hoppensteadt, J. Fareed, 1991, Thrombosis research.

The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm

Jilly F. Evans, D. Rader, Lei Zhao, 2004, Nature Medicine.

Inhibitory effects of TFPI variants on thrombin and factor Xa generation in fibrinogen-deficient human plasma.

J. Fareed, D. Hoppensteadt, W. Jeske, 1994, Thrombosis research.

Anticoagulant action of synthetic tight binding inhibitors of thrombin in vitro and in vivo.

F. Markwardt, J. Hauptmann, B. Kaiser, 1985, Thrombosis research.

Studies on antithrombotic effects of recombinant hirudin.

F. Markwardt, B. Kaiser, G. Nowak, 1989, Thrombosis research.

Antagonism of the antithrombotic and anti‐atherosclerotic actions of aspirin by rofecoxib in the cholesterol‐fed rabbit

K. Schrör, G. Kaber, B. Kaiser, 2011, British journal of pharmacology.

Factor Xa Inhibitors in the Control of Thrombogenesis

D. Hoppensteadt, J. Fareed, W. Jeske, 1999 .

Pharmacological characterization of a new structural variant of 4-amidinophenylalanine amide-type synthetic thrombin inhibitor.

F. Markwardt, J. Hauptmann, B. Kaiser, 1989, Die Pharmazie.

Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro--modulatory action of glycosaminoglycans.

D. Hoppensteadt, J. Fareed, W. Jeske, 1994, Thrombosis research.

Tissue Factor Pathway Inhibitor: Potential Implications in the Treatment of Cardiovascular Disorders

D. Hoppensteadt, J. Fareed, B. Kaiser, 2002 .

Anticoagulant potential of synthetic and recombinant inhibitors of factor Xa and thrombin in vitro

J. Hauptmann, B. Kaiser, 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Antithrombotic and haemorrhagic effects of the naturally occurring thrombin inhibitor hirudin.

F. Markwardt, B. Kaiser, 1988, Folia haematologica.